US Patent

US11446246 — Suspensions and diluents for metronidazole and baclofen

Method of Use · Assigned to Azurity Pharmaceuticals Inc · Expires 2037-09-08 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects suspensions of metronidazole or baclofen, including various additives, for use as a formulation.

USPTO Abstract

Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.

Drugs covered by this patent

Lioresal (BACLOFEN)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3433`	—	Lioresal

Patent Metadata

Patent number: US11446246
Jurisdiction: US
Classification: Method of Use
Expires: 2037-09-08
Drug substance claim: No
Drug product claim: No
Assignee: Azurity Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.